Overview of This Study:

This study involved four major activities in estimating the current size of the Cell Isolation Market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Major Growth Driving Factors:

Market growth is driven by the the increasing number of patients suffering from cancer and infectious diseases, increasing government funding for cell-based research, the growing focus on personalized medicine and technological advancements.

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the cell isolation market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry have been identified through extensive secondary research
# The revenues generated by leading players operating in the cell isolation market have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479

Expected Revenue Growth:

The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9 billion in 2020, at a CAGR of 16.8%.

Data Triangulation:

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Recent Developments:

# In May 2019, Thermo Fisher Scientific acquired Brammer Bio with the aim to expand capabilities to support the high growth gene and cell therapy market.

# In October 2018, Merck opened its M Lab Collaboration Center in São Paulo

# In May 2019, Beckman Coulter launched ClearLLab 10C System

Opportunity: Emerging Markets

Emerging countries, especially in the Asia Pacific region, are expected to become a focal point for growth in the cell isolation market. The increasing investments in cell biology research and the growing presence of market players in emerging regions are the major factors responsible for the high growth of the cell isolation market in these countries. For instance, pharmaceutical companies based in India are making significant investments in RD in order to introduce new drugs in the market.

Dr. Reddy’s Laboratories, one of the major players in the Indian pharmaceutical market, spent USD 297 million on RD in 2017. Such investments are expected to increase the demand for cell isolation products in the country in the coming years. Also, in May 2017, India’s Cabinet Committee on Economic Affairs announced plans to invest ~USD 250 million-half of it to be funded by the World Bank-through 2023 toward industry-academic collaborations to develop vaccines, therapeutics, and medical devices.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=103931479

End Users:

In 2019, biotechnology and biopharmaceutical companies segment accounted for the largest share in the market, by end user

The cell isolation market is segmented into hospitals and diagnostic laboratories, biotechnology and biopharmaceutical companies, research laboratories and institutes, and other end users based on end users. In 2019, the biotechnology and biopharmaceutical companies segment accounted for the largest share. The large share of this end-user segment can be attributed to the widespread adoption of advanced instruments in cell-based experiments and cancer research in biotechnology and biopharmaceutical companies, as well as the increasing number of RD facilities globally.